can semaglutide cause kidney issues cuts risk in obesity | Journal of Endocrinological Investigation Ozempic and GLP-1 Drugs: Risk

The magnitude and rate of bone loss in ovariectomized mice differs among inbred strains as determined by longitudinal in vivo micro-computed tomography

Now let's dive into why we are all here, because this is going to be a huge conversation

Combining medication with behavior change is powerful because the patient is more likely to experience early success, leading to a greater likelihood to stick with the program and transform a new habit into permanent lifestyle change

18F-Labelled exendin to image GLP-1 receptor-expressing tissues: from niche to blockbuster

Its a necessity The National Hispanic Health Foundation, National Hispanic Council on Aging, League of United Latin American Citizens, American Diabetes Association and the national Latina advocacy organization MANA published a joint policy brief in February, calling on New Mexico to allocate state funding to support Medicaid coverage of weight loss drugs to treat obesity